1. Home
  2. BAOS vs APRE Comparison

BAOS vs APRE Comparison

Compare BAOS & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Baosheng Media Group Holdings

BAOS

Baosheng Media Group Holdings

N/A

Current Price

$0.24

Market Cap

9.1M

ML Signal

N/A

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

N/A

Current Price

$0.73

Market Cap

10.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BAOS
APRE
Founded
2018
2006
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
10.8M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
BAOS
APRE
Price
$0.24
$0.73
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $3.73
AVG Volume (30 Days)
★ 4.6M
143.1K
Earning Date
04-30-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.22
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.55
52 Week High
$5.21
$1.69

Technical Indicators

Market Signals
Indicator
BAOS
APRE
Relative Strength Index (RSI) 29.04 47.94
Support Level N/A $0.70
Resistance Level $0.36 $0.79
Average True Range (ATR) 0.03 0.05
MACD 0.03 -0.00
Stochastic Oscillator 14.75 33.94

Price Performance

Historical Comparison
BAOS
APRE

About BAOS Baosheng Media Group Holdings

Baosheng Media Group Holdings Ltd is a China-based online marketing solution provider. The company provides internet marketing, short-video and V-log marketing, content production and operation, e-commerce marketing, data platform services, and AI technology-related services. It also offers customized marketing solutions and channel marketing services through partnerships with internet platforms such as Tencent, Alibaba, ByteDance, and Kuaishou.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: